Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study

Jacob J. Henderson; Anirban Das; Daniel A. Morgenstern; Sumedha Sudhaman; Vanessa Bianchi; Jill Chung; Logine Negm; Melissa Edwards; David E. Kram; Michael Osborn; Cynthia Hawkins; Eric Bouffet; Yoon Jae Cho; Uri Tabori

doi:10.1200/PO.21.00286

Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study

Jacob J. Henderson, Anirban Das, Daniel A. Morgenstern, Sumedha Sudhaman, Vanessa Bianchi, Jill Chung, Logine Negm, Melissa Edwards, David E. Kram, Michael Osborn, Cynthia Hawkins, Eric Bouffet, Yoon Jae Cho, Uri Tabori

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English (US)
Article number	e2100286
Journal	JCO Precision Oncology
Volume	6
DOIs	https://doi.org/10.1200/PO.21.00286
State	Published - 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/PO.21.00286

Cite this

Henderson, J. J., Das, A., Morgenstern, D. A., Sudhaman, S., Bianchi, V., Chung, J., Negm, L., Edwards, M., Kram, D. E., Osborn, M., Hawkins, C., Bouffet, E., Cho, Y. J., & Tabori, U. (2022). Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. JCO Precision Oncology, 6, Article e2100286. https://doi.org/10.1200/PO.21.00286

@article{83245d45ebf441feac74a8a0949efbcb,

title = "Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study",

author = "Henderson, {Jacob J.} and Anirban Das and Morgenstern, {Daniel A.} and Sumedha Sudhaman and Vanessa Bianchi and Jill Chung and Logine Negm and Melissa Edwards and Kram, {David E.} and Michael Osborn and Cynthia Hawkins and Eric Bouffet and Cho, {Yoon Jae} and Uri Tabori",

note = "Funding Information: AD would like to acknowledge the kind support of the St Baldrick{\textquoteright}s Foundation International Scholar Program (with generous support from the Team Campbell Foundation; Grant number: 697257) and the SickKids Research Training Center Clinician-Scientist Training Program (Fall 2019 award).",

year = "2022",

doi = "10.1200/PO.21.00286",

language = "English (US)",

volume = "6",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation

T2 - An IRRDC Study

AU - Henderson, Jacob J.

AU - Das, Anirban

AU - Morgenstern, Daniel A.

AU - Sudhaman, Sumedha

AU - Bianchi, Vanessa

AU - Chung, Jill

AU - Negm, Logine

AU - Edwards, Melissa

AU - Kram, David E.

AU - Osborn, Michael

AU - Hawkins, Cynthia

AU - Bouffet, Eric

AU - Cho, Yoon Jae

AU - Tabori, Uri

N1 - Funding Information: AD would like to acknowledge the kind support of the St Baldrick’s Foundation International Scholar Program (with generous support from the Team Campbell Foundation; Grant number: 697257) and the SickKids Research Training Center Clinician-Scientist Training Program (Fall 2019 award).

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85127577732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127577732&partnerID=8YFLogxK

U2 - 10.1200/PO.21.00286

DO - 10.1200/PO.21.00286

M3 - Article

AN - SCOPUS:85127577732

SN - 2473-4284

VL - 6

JO - JCO Precision Oncology

JF - JCO Precision Oncology

M1 - e2100286

ER -

Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this